LifeScience Clinical & Diagnostic
Samsung Bioepis and Phrontline Partner to Develop Next-Generation Bispecific, Dual-Payload ADC Therapies for Solid Tumours
Samsung Bioepis and Phrontline will co-develop two investigational antibody-drug conjugate (ADC) assets directed against targets expressed in a broad r...
October 22, 2025 | News
Alphamab Oncology and CSPC’s HER2-Targeting ADC JSKN003 Receives Breakthrough Therapy Designation in China for Advanced Colorectal Cancer
Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targ...
October 21, 2025 | News
Sanofi’s Efluelda (Fluzone High-Dose) Cuts Influenza Hospitalisations by 31.9% in Adults Aged 65+
Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by a...
October 21, 2025 | News
PeptiDream, PDRadiopharma, and Curium Launch Registrational Phase 2 Trial in Japan for 64Cu-PSMA-I&T Targeting Prostate Cancer
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587), PDRadiopharm...
October 17, 2025 | News
Mabwell’s CDH17-Targeting ADC 7MW4911 Receives NMPA IND Clearance for Advanced Solid Tumours
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D cod...
October 15, 2025 | News
Ascletis Selects ASC35 as Once-Monthly, Dual GLP-1/GIP Peptide Agonist Candidate for Obesity Treatment
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, whic...
October 14, 2025 | News
Everest Medicines Secures Dual IND Approvals for EVM14, Its First Internally Developed Therapeutic mRNA Cancer Vaccine
EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from both China's National Medic...
October 14, 2025 | News
Lundbeck’s Bexicaserin Receives Breakthrough Therapy Designation in China for Severe Childhood Epilepsies
Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies Novel 5HT2C mechanism des...
October 14, 2025 | News
Henlius’ HANSIZHUANG Meets Primary Endpoint in Phase 3 Gastric Cancer Trial
The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Applicati...
October 13, 2025 | News
Renalys Pharma Completes Primary Endpoint Data Collection in Phase III Sparsentan Trial for IgA Nephropathy
Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") announced that it has completed data collection for the primary endpoint in the Phase I...
October 13, 2025 | News
C-Ray Therapeutics Commends Biokin on NMPA Approval for Groundbreaking [177Lu]-BL-ARC001 Radiopharmaceutical
C-Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner, Biokin Pharmaceutical, on receiving implied approval from the N...
October 13, 2025 | News
Aptamer Group Secures Major Deal with Top Global Pharma to Advance Optimer® Radiopharmaceuticals
Development agreement applies Optimer® binders to cancer imaging and therapeutics Platform demonstrates versatility across multiple ther...
October 10, 2025 | News
Australia’s Cyteph Completes Recruitment for Its First-in-Human Trial of CYT-101 in Glioblastoma
Cyteph Pty Ltd, a biotechnology company developing novel immunotherapies for difficult-to-treat cancers, today announced that it has successfully completed...
October 09, 2025 | News
Thermo Fisher Introduces Gene Expression Profiling Test to Improve Precision in Lung Transplant Rejection Assessment
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury Thermo Fisher Scientific, the world leader in serv...
October 09, 2025 | News
Most Read
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
